Turn Therapeutics Inc. (TTRX)
NASDAQ: TTRX · Real-Time Price · USD
3.580
+0.100 (2.87%)
Feb 26, 2026, 1:00 PM EST - Market open

Turn Therapeutics Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Turn Therapeutics stock has a target of 8.00, which predicts a 123.46% increase from the current stock price of 3.58.

Price Target: $8.00 (+123.46%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$8.00$8.00$8.00$8.00
Change+123.46%+123.46%+123.46%+123.46%
* Price targets were last updated on Jan 20, 2026.

Analyst Ratings

According to 1 stock analyst, the rating for Turn Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingJan '26Feb '26
Strong Buy11
Buy00
Hold00
Sell00
Strong Sell00
Total11

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
D. Boral Capital
D. Boral Capital
Strong Buy
Maintains
$8
Strong BuyMaintains$8+123.46%Jan 20, 2026
D. Boral Capital
D. Boral Capital
Strong Buy
Initiates
$8
Strong BuyInitiates$8+123.46%Dec 29, 2025

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
204.00M
EPS This Year
-0.15
from -0.07
EPS Next Year
-0.11
from -0.15
Fiscal YearFY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
----204.00M2.60M
Revenue Growth
------98.73%
EPS
--0.09-0.07-0.15-0.11-0.26
EPS Growth
------
Forward PE
------
No. Analysts
---444
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue202520262027
Highn/a420.0M
Avgn/a204.0M
Lown/an/a

Revenue Growth

Revenue Growth202520262027
High--
Avg--
Low--

EPS Forecast

EPS202520262027
High-0.14-0.11
Avg-0.15-0.11
Low-0.16-0.12

EPS Growth

EPS Growth202520262027
High--
Avg--
Low--
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.